Planmeca has successfully finalized the acquisition of the treatment unit and instrument business from a major diversified global medical manufacturer. This strategic transaction represents a significant consolidation of the global dental equipment market, bringing together two of the most technically advanced portfolios in the industry. The strategic rationale for the move centers on the high degree of industrial synergy between the target’s mechanical instrumentation excellence and the group's existing strength in digital 3D imaging and software interfaces. By integrating the target’s renowned heritage and manufacturing capabilities, the group establishes itself as a dominant single-source provider for complete dental operatory solutions. The acquisition includes the full transfer of iconic branding and intellectual property, allowing the organization to capitalize on a massive global installed base. The partnership is designed to accelerate the development of "connected" dental suites, where high-precision handpieces are synchronized with digital diagnostic platforms. This integration reinforces the group’s standing as a primary technical enabler for dental professionals, ensuring long-term technical durability and operational caliber across its international operational hubs.

The transaction values KAVO DENTAL at an EV/Revenue multiple of LOGIN.

This transaction is part of the Healthcare & Pharma industry, which currently tracks an average EBITDA multiple of 12.8x since the beginning of 2026, 1.8% increase compared to 2025. This data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.